| dc.contributor.author | Hauser, SL | en_US |
| dc.contributor.author | Bar-Or, A | en_US |
| dc.contributor.author | Comi, G | en_US |
| dc.contributor.author | Giovannoni, G | en_US |
| dc.contributor.author | Hartung, H-P | en_US |
| dc.contributor.author | Hemmer, B | en_US |
| dc.contributor.author | Lublin, F | en_US |
| dc.contributor.author | Montalban, X | en_US |
| dc.contributor.author | Rammohan, KW | en_US |
| dc.contributor.author | Selmaj, K | en_US |
| dc.contributor.author | Traboulsee, A | en_US |
| dc.contributor.author | Wolinsky, JS | en_US |
| dc.contributor.author | Arnold, DL | en_US |
| dc.contributor.author | Klingelschmitt, G | en_US |
| dc.contributor.author | Masterman, D | en_US |
| dc.contributor.author | Fontoura, P | en_US |
| dc.contributor.author | Belachew, S | en_US |
| dc.contributor.author | Chin, P | en_US |
| dc.contributor.author | Mairon, N | en_US |
| dc.contributor.author | Garren, H | en_US |
| dc.contributor.author | Kappos, L | en_US |
| dc.contributor.author | Clinical, OPERAIOPERAII | en_US |
| dc.date.accessioned | 2017-01-24T14:27:45Z | |
| dc.date.available | 2016-12-07 | en_US |
| dc.date.issued | 2017-01-19 | en_US |
| dc.date.submitted | 2017-01-03T08:18:54.230Z | |
| dc.identifier.issn | 0028-4793 | en_US |
| dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/18940 | |
| dc.description.sponsorship | Supported by F. Hoffmann–La Roche. | en_US |
| dc.format.extent | 221 - 234 | en_US |
| dc.relation.ispartof | NEW ENGLAND JOURNAL OF MEDICINE | en_US |
| dc.rights | From New England Journal of Medicine, Hauser, S.L. et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, 376:221-234. DOI: 10.1056/NEJMoa1601277. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission. | |
| dc.title | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis | en_US |
| dc.type | Article | |
| dc.rights.holder | Copyright © 2016 Massachusetts Medical Society. All rights reserved. | |
| dc.identifier.doi | 10.1056/NEJMoa1601277 | en_US |
| pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000392199100006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
| pubs.issue | 3 | en_US |
| pubs.notes | No embargo | en_US |
| pubs.publication-status | Published | en_US |
| pubs.volume | 376 | en_US |
